News

Public · Published

ARDX: Revenue grew 19% as IBSRELA led; guidance was reaffirmed and profitability remains targeted for 2027

Ardelyx reported that third-quarter product revenue rose 19% year over year to $125.5 million, led by IBSRELA. Its net loss narrowed to $0.7 million. The company reaffirmed its 2026 product and expense guidance and continued to target profitability in 2027.

Published:

Updated:

What happened

Ardelyx reported that third-quarter product revenue rose 19% year over year to $125.5 million, led by IBSRELA. Its net loss narrowed to $0.7 million. The company reaffirmed its 2026 product and expense guidance and continued to target profitability in 2027.

Confirmed

Global impact / market context

Higher product revenue and a narrower loss indicate that sales growth is moving alongside a smaller reported loss, but Ardelyx has not said it is already profitable. Reaffirmed guidance signals no change to its stated 2026 product and expense expectations.

Analyst inference

The update links IBSRELA-led sales growth with the company’s path toward a 2027 profitability target. For investors, the key financial connection is whether product revenue can grow enough, while expenses remain within guidance, to support that target.

Analyst inference

What to watch

  1. Track whether future reports show product revenue continuing to grow and IBSRELA remaining the leading contributor, since sales growth supports the stated path toward profitability. Analyst inference
  2. Compare reported 2026 product revenue and expenses with the reaffirmed guidance; a change in either could alter expectations for the company’s spending and sales trajectory. Analyst inference
  3. Watch for updates on the 2027 profitability target and the reported net loss, which narrowed to $0.7 million in the third quarter. Analyst inference

Evidence

  • Original source link unavailable